The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria:
* Bladder cancer diagnosis between January 1, 2016 and December 31, 2020
* Tumor stage N0/x and M0/x plus any of the following: Tis (primary CIS); TaG3/HG (high-grade non-invasive papillary carcinoma); or T1 (tumor invading subepithelial connective tissue)
* Minimal follow-up time of 5 years unless there is premature death event
Exclusion criteria:
* Tumor stage at diagnosis classified as TaG1-2, T2-T4, N1-3, or M1
* History of radical cystectomy performed either prior to the HR-NMIBC index diagnosis or for an indication unrelated to the index HR-NMIBC
* Participation in any interventional clinical trial during the observation period
Primary outcome measure(s)
Treatment Patterns: Type of Therapeutic Approach — Up to 5 years Number of participants receiving different types of therapeutic approach including bacillus calmette-guerin (BCG) therapy, chemotherapy, radiotherapy, immunotherapy, or targeted therapy will be reported.
Treatment Patterns: Type of Surgery — Up to 5 years Number of participants undergoing different types of surgery, including transurethral resection of the bladder tumor (TURBT), repeat TURBT or cystectomy will be reported.
Treatment Patterns by Subpopulation: Tumor Stage — Up to 5 years Number of participants by tumor stage will be reported.
Treatment Patterns by Subpopulation: Histology — Up to 5 years Number of participants by histology will be reported.
Treatment Patterns by Subpopulation: Line of Therapy — Up to 5 years Number of participants by line of therapy will be reported,
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
